OnePass Medical

Company Overview

Snapshot

Founded in July 2018 by Jacob BenArie and Jesse Yishai Lachter, OnePass Medical operates with 1-10 employees. The company has secured $3.47 million in total capital across 3 funding rounds from 1 investor. In April 2021, OnePass Medical received a grant from the Israel Innovation Authority.

Business overview

OnePass Medical develops a disposable platform for interventional endoscopy and bronchoscopy treatments, primarily serving the healthcare and life sciences sectors. Its core product, InstaFAN, is a biopsy device designed to collect multiple tissue samples from different areas of a tumor in a single procedure, enhancing diagnostic accuracy and reducing procedure time. The platform is particularly effective for endoscopy-ultrasound guided biopsies and bronchoscopies, with potential future applications in therapeutic areas such as multipronged drug delivery and ablation. The company operates within the Medical Devices, Diagnostics Devices, and Medical Treatment & Therapeutics categories, utilizing ultrasound technology.

Company Intelligence Q&A

What is OnePass Medical's primary product?

OnePass Medical's primary product is InstaFAN, a biopsy device for collecting multiple tissue samples from different areas of a tumor in a single procedure, enhancing diagnostic accuracy and reducing time and repeat biopsies.

When was OnePass Medical founded?

OnePass Medical was founded in July 2018.

Who are the founders of OnePass Medical?

The founders of OnePass Medical are Jacob BenArie and Jesse Yishai Lachter.

What strategic collaborations does OnePass Medical have?

OnePass Medical has two ongoing strategic development collaborations with Mayo Clinic, both of which include licensing agreements. One collaboration focuses on gastro-intestinal applications of the InstaFAN platform.

What type of funding did OnePass Medical receive in April 2021?

In April 2021, OnePass Medical received a grant from the Israel Innovation Authority.